Outlook into the Worldwide Anti-Diabetic Drugs Industry to 2025 - Emerging Players and Market Lucrativeness - ResearchAndMarkets.com

DUBLIN--()--The "Anti-Diabetic Drugs Market - Forecasts from 2020 to 2025" report has been added to ResearchAndMarkets.com's offering.

The Global Anti-diabetic Drug Market as valued at US$70.687 billion in 2019.

The rising prevalence of diabetes worldwide is the major driver of the global anti-diabetic drug market. According to the International Diabetes Foundation, in 2019, approximately 463 million adults (20-79 years) suffered from diabetes which is projected to rise 700 million by 2045. The major market growth is attributed to the increasing number of patients suffering from Type 2 diabetes in different regions. According to the International Diabetes Foundation, the number of people with Type 2 diabetes is increasing in many countries.

Unhealthy dietary habits among people of all ages have led to a drastic rise in diabetic patients globally. Furthermore, the rising cost of treating diabetes is also spurring the demand for anti-diabetic drugs, thereby bolstering the global anti-diabetic drug market growth. According to the International Diabetes Foundation, in 2019, diabetes led to more than US$750 billion in health expenditure which is 10 percent of total spending on adults. Global pharmaceutical companies are funneling investments in research and development to develop advanced anti-diabetic drugs as per the growing requirement. The growing geriatric population is another factor that is driving the market growth of anti-diabetic drugs. According to the International Diabetes Foundation, 1 in 5 of the old people aged 65 years and above have diabetes. Rising government expenditure and health awareness campaigns to treat diabetes effectively is also boosting the global anti-diabetic drug market growth.

The global anti-diabetic drug market is segmented by diabetes type, drug type, route of administration, sales channel, and geography. On the basis of diabetes type, the global anti-diabetic drug market is segmented as Type 1 and Type 2. The global anti-diabetic drug market segmentation based on the drug type is done by Amylinomimetic dru, Biguanide, Alpha-glucosidase inhibitors, Sodium-glucose transporter (SGLT) 2 inhibitors, and others. By route of administration, the market segmentation is done as oral and insulin. By the sales channel, the global anti-diabetic drug market is segmented as prescription and over-the-counter (OTC).

The prescribed anti-diabetic drug market holds a noteworthy market share throughout the forecast period. This is because these drugs are prescribed to patients by doctors with other diabetes-related therapies. Moreover, the wrong dosage of some drugs can lead to a harmful impact on the patient's health. However, many pharmaceutical companies are launching OTC anti-diabetic drugs, especially in the emerging economies as these are cheaper than the prescribed drugs. Thus, the OTC ant-diabetic drug market will experience a significant CAGR between 2019 and 2025 owing to the rising sales in developing economies.

Prominent key market players in the Global Anti-diabetic Drug Market include AstraZeneca plc, Pfizer Inc., Merck & Co., Inc., Novo Nordisk A/S, Eli Lilly and Company, Glenmark Pharmaceuticals Ltd., Abbott, and Boehringer Ingelheim International GmbH among others. These companies hold a noteworthy share in the market on account of their good brand image and product offerings. Major players in the Global Anti-diabetic Drug Market have been covered along with their relative competitive position and strategies. The report also mentions recent deals and investments of different market players over the last two years.

Key Topics Covered:

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamics

4.1. Market Drivers

4.2. Market Restraints

4.3. Porters Five Forces Analysis

4.4. Product Pipeline

4.5. Industry Value Chain Analysis

5. Global Anti-Diabetic Drug Market Analysis, By Diabetes Type

5.1. Introduction

5.2. Type I

5.3. Type II

6. Global Anti-Diabetic Drug Market Analysis, By Drug Type

6.1. Introduction

6.2. Amylinomimetic drug

6.3. Biguanides

6.4. Alpha-glucosidase inhibitors

6.5. Sodium-glucose transporter (SGLT) 2 inhibitors

6.6. Others

7. Global Anti-Diabetic Drug Market Analysis, By Route of Administration

7.1. Introduction

7.2. Oral

7.3. Insulin

8. Global Anti-Diabetic Drug Market Analysis, By Sales Channel

8.1. Introduction

8.2. Prescription

8.3. Over-The-Counter (OTC)

9. Global Anti-Diabetic Drug Market Analysis, By Geography

9.1. Introduction

9.2. North America

9.3. South America

9.4. Europe

9.5. Middle East and Africa

9.6. Asia Pacific

10. Competitive Environment and Analysis

10.1. Major Players and Strategy Analysis

10.2. Emerging Players and Market Lucrativeness

10.3. Mergers, Acquisitions, Agreements, and Collaborations

10.4. Vendor Competitiveness Matrix

11. Company Profiles

11.1. AstraZeneca plc

11.2. Pfizer Inc.

11.3. Merck & Co., Inc.

11.4. Novo Nordisk A/S

11.5. Eli Lilly and Company

11.6. Glenmark Pharmaceuticals Ltd.

11.7. Abbott

11.8. Boehringer Ingelheim International GmbH

For more information about this report visit https://www.researchandmarkets.com/r/1e5opm

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900